Arcus Biosciences, Inc. Contract Liability (Deferred Revenue)
Arcus Biosciences, Inc. (RCUS) had Contract Liability (Deferred Revenue) of $19.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $19.00M.
- 2026-03-31: Contract with Customer, Liability, Current $34.00M.
- 2025-12-31: Contract with Customer, Liability, Current $35.00M.
- 2025-09-30: Contract with Customer, Liability, Current $52.00M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $19.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $34.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $35.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $52.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $71.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $72.00M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $85.00M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $105.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $113.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $124.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $91.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $103.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $103.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $97.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $97.00M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $103.29M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $90.12M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $89.31M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $102.00M 10-K · filed 2023-02-28 | $102.00M 10-K · filed 2022-02-23 |
| 2021-09-30 | $74.34M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $74.57M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $74.57M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $74.57M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $115.61M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $7.00M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $7.00M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $7.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $7.00M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $7.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $7.00M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |